This review summarizes the indications, contraindications, genetic resistance, and drug interactions of new oral antiplatelet therapies.
Answers are grounded in this paper and cite their sources.
Newer potent antiplatelets may guide ACS prescribing; leaves open comparative effectiveness and resistance testing needs.
New and more potent oral antiplatelet agents have shown better clinical outcomes over the last few years. This article reviews the latest oral antiplatelet therapies available, their indications and contraindications, genetic resistance, and major drug interactions.
No takes yet. Share an insight, caveat, or question.
Travis Jeffords (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: